<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621852</url>
  </required_header>
  <id_info>
    <org_study_id>VERSION 2 04/2017</org_study_id>
    <nct_id>NCT03621852</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of the Diagnostic Efficacy of a EUS Guided FNB Needle (AQUIRE®)</brief_title>
  <official_title>Prospective Evaluation of the Diagnostic Efficacy of a EUS Guided FNB Needle (AQUIRE®) in Tumors of the Pancreas, Submucosal Tumors and Lymph Node Disease of the Upper GI Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study investigates the efficacy of a new Endoultrasound guided fine needle biopsy
      (EUS-FNB) device (AquireTM Boston Scientific= AQUIRE®) for obtaining histological tissue
      cylinders in the diagnosis of solid pancreatic tumors, submucosal tumors of the upper
      gastrointestinal tract (esophagus, stomach, duodenum) and lymph node disease..
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The AquireTM FNB device uses a triple point tip that is designed to maximize tissue capture
      and minimize fragmentation.

      The efficiency of the 22 Gauge needle is evaluated in a prospective single arm study. The
      material obtained will be collected for formalin fixation and analyzed by a pathologist
      blinded for the type of needle device.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>tissue yield</measure>
    <time_frame>12 month after FNB</time_frame>
    <description>The primary outcome of the present study is to analyze the percentage in which a representative histological sample can be obtained by EUS-FNB (quality score 3 as defined by Payne et al.).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Tumors of the Pancreas</condition>
  <condition>Submucosal Tumor of Gastrointestinal Tract (Disorder)</condition>
  <condition>Lymph Node Disease</condition>
  <arm_group>
    <arm_group_label>Endoultrasound guided FNB</arm_group_label>
    <description>Patients with tumors of the pancreas, submucosal tumors or lymphnode disease of the upper gastrointestinal tract, which have to undergo EUS guided FNB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoultrasound guided FNB</intervention_name>
    <description>EUS FNB with Aquire TM device</description>
    <arm_group_label>Endoultrasound guided FNB</arm_group_label>
    <other_name>EUS FNB with Aquire TM device</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing EUS FNB with solid pancreatic tumors, submucosal tumors or lymph node
        disease of the upper gastrointestinal tract.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Indication for EUS FNB with solid pancreatic tumors, submucosal tumors or lymph node
             disease of the upper gastrointestinal tract will be included

        Exclusion Criteria:

          -  Cystic pancreatic tumors

          -  Contraindication for EUS FNB

          -  Lesion of interest cannot be reached endosonographically
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ulrike Denzer, PD. Dr. med.</last_name>
    <phone>004964215866460</phone>
    <email>uwdenzer@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Waldthaler, Dr.med.</last_name>
    <phone>004964215866460</phone>
    <email>alexanderwaldthaler@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätskliniken Gießen und Marburg, Standort Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Denzer, PD.Dr.med.</last_name>
      <phone>004964215866460</phone>
      <email>uwdenzer@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ulrike Denzer, PD. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Philipps University Marburg Medical Center</investigator_affiliation>
    <investigator_full_name>Ulrike Denzer</investigator_full_name>
    <investigator_title>Prof. Dr. med. Ulrike Denzer, Head of the department of endoscopy</investigator_title>
  </responsible_party>
  <keyword>Endosonography</keyword>
  <keyword>fine needle biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

